The goals of the Genetic Epidemiology and Risk Assessment (GERA) Program are to: 1) Utilize the tremendous advances in genetics and molecular biology in order to understand genetic, environmental, and gene-environment interactions in the etiology of cancer in human populations;2) Utilize these same advances in order to understand the molecular epidemiology of cancer prognosis and survivorship;and 3) Develop and apply novel statistical and informatics methods for the design and analysis of genetic and molecular epidemiology studies. Our cancer etiology studies use family-based, case-control and cohort study designs and focus on the genetic epidemiology of cancer, premalignant conditions, and intermediate phenotypes, as well as non-genetic risk factors and descriptive epidemiology. We are also addressing etiologic heterogeneity based on tumor phenotype. Our cancer prognosis research focuses on host factors, including genetic and serum biomarkers as well as lifestyle factors that influence prognosis;tumor biomarkers;and survivorship. Novel methods for the design and analysis of genetic and molecular epidemiologic studies are being developed, building on our expertise in biostatistics, medical informatics and bioinformatics. To achieve these goals we have assembled a team of 32 multidisciplinary investigators from over 10 divisions or departments. Total peer-reviewed funding is $8.81 M from 32.6 assigned grants, with 71% coming from the National Cancer Institute. Since 2008, the program has generated 622 publications, 43% reflecting intra-programmatic collaborations and 61% reflecting inter-programmatic collaborations. Notable contributions have been made in the epidemiology of pancreatic, lung, ovarian, breast, colon, lymphoma, and mammographic breast density, as well as to the statistical genetics and medical and bioinformatics literature. Leadership of the program is provided by Drs. Cerhan and Parker. The program makes extensive use of shared facilities. In the next 5 years, we will continue our innovative research in cancer etiology and prognosis with a focus on genomics, development and application of novel technologies and methods, and translation to the clinic and population as well as back to the lab to inform biology.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA015083-40
Application #
8682941
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-04-25
Project End
2019-02-28
Budget Start
2014-07-11
Budget End
2015-02-28
Support Year
40
Fiscal Year
2014
Total Cost
$402,631
Indirect Cost
$149,608
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97

Showing the most recent 10 out of 340 publications